Search Results - "Gállego Pérez‐Larraya, J."

Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study by Velasco, R., Mercadal, S., Vidal, N., Alañá, M., Barceló, M. I., Ibáñez-Juliá, M. J., Bobillo, S., Caldú Agud, R., García Molina, E., Martínez, P., Cacabelos, P., Muntañola, A., García-Catalán, G., Sancho, J. M., Camro, I., Lado, T., Erro, M. E., Gómez-Vicente, L., Salar, A., Caballero, A. C., Solé-Rodríguez, M., Gállego Pérez-Larraya, J., Huertas, N., Estela, J., Barón, M., Barbero-Bordallo, N., Encuentra, M., Dlouhy, I., Bruna, J., Graus, F.

“…Introduction To assess the management of immunocompetent patients with primary central nervous system lymphomas (PCNSL) in Spain. Methods Retrospective…”
Get full text

Seizure‐susceptible brain regions in glioblastoma: identification of patients at risk by Cayuela, N., Simó, M., Majós, C., Rifà‐Ros, X., Gállego Pérez‐Larraya, J., Ripollés, P., Vidal, N., Miró, J., Gil, F., Gil‐Gil, M., Plans, G., Graus, F., Bruna, J.

“…Background and purpose The main aim of this study was to identify which patients with glioblastoma multiforme (GBM) have a higher risk of presenting seizures…”
Get full text

Seasonal periodicity in SUNCT syndrome by Irimia, P, Gállego-Pérez Larraya, J, Martinez-Vila, E

Get more information

International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma by Rodriguez-Otero, Paula, Usmani, Saad, Cohen, Adam D, van de Donk, Niels W C J, Leleu, Xavier, Gállego Pérez-Larraya, Jaime, Manier, Salomon, Nooka, Ajay K, Mateos, Maria Victoria, Einsele, Hermann, Minnema, Monique, Cavo, Michele, Derman, Benjamin A, Puig, Noemi, Gay, Francesca, Ho, P Joy, Chng, Wee-Joo, Kastritis, Efstathios, Gahrton, Gösta, Weisel, Katja, Nagarajan, Chandramouli, Schjesvold, Fredik, Mikhael, Joseph, Costa, Luciano, Raje, Noopur S, Zamagni, Elena, Hájek, Roman, Weinhold, Niels, Yong, Kwee, Ye, Jing Christine, Sidhana, Surbhi, Merlini, Giampaolo, Martin, Tom, Lin, Yi, Chari, Ajai, Popat, Rakesh, Kaufman, Jonathan L

“…Multiple myeloma remains an incurable disease, despite the development of numerous drug classes and combinations that have contributed to improved overall…”
Get full text

Update on the diagnosis of encephalitis by Arbizu, J., Gállego Pérez-Larraya, J., Hilario, A., Gómez Grande, A., Rubí, S., Camacho, V.

“…Autoimmune encephalitis are brain inflammatory processes that are classified into two main groups according to the underlying pathogenic mechanism: antibodies…”
Get full text

CLIPPERS syndrome: A case report by Esparragosa Vázquez, I., Valentí-Azcárate, R., Gállego Pérez-Larraya, J., Riverol Fernández, M.

Get full text

Descripción de una serie de pacientes con diagnóstico de enfermedad priónica by Ortega-Cubero, S, Pagola, I, Luquin, M.R, Viteri, C, Pastor, P, Gállego Pérez-Larraya, J, de Castro, P, Domínguez, I, Irimia, P, Martínez-Vila, E, Arbizu, J, Riverol, M

“…Resumen Introducción Las prionopatías representan hasta el 62% de los casos de demencia rápidamente progresiva (DRP) en los que se alcanza un diagnóstico…”
Get full text

Síndrome CLIPPERS. A propósito de un caso by Esparragosa Vázquez, I., Valentí-Azcárate, R., Gállego Pérez-Larraya, J., Riverol Fernández, M.

Get full text

Clinical and neuroimaging characteristics of 14 patients with prionopathy: a descriptive study by Ortega-Cubero, S., Pagola, I., Luquin, M.R., Viteri, C., Pastor, P., Gállego Pérez-Larraya, J., de Castro, P., Domínguez, I., Irimia, P., Martínez-Vila, E., Arbizu, J., Riverol, M.

“…Prionopathy is the cause of 62% of the rapidly progressive dementias (RPD) in which a definitive diagnosis is reached. The variability of symptoms and signs…”
Get full text

Facial diplegia and vestibular neuritis secondary to HIV seroconversion syndrome by Gállego Pérez-Larraya, J, Riverol, M

Get more information

P08.04 Glioblastoma and Alzheimer pathology: lessons from a single case with practical implications and need for further research by Gállego Pérez-Larraya, J, Esparragosa, I, Puigdelloses, M, Idoate, M, Alonso, M

“…Abstract BACKGROUND Glioblastoma (GBM) and Alzheimer’s disease (AD) are frequent among the elderly: about 50% of all GBM patients are 65 years or older, and…”
Get full text

P01.061 Autologous dendritic cells vaccination and standard radio-chemotherapy in patients with newly diagnosed glioblastoma: a retrospective single-center series by Esparragosa, I, Inoges, S, de Cerio, A L, Espinos, J, Aristu, J, Puigdelloses, M, Alonso, M, Tejada-Solis, S, Díez-Valle, R, Gállego Pérez-Larraya, J

“…Abstract Background Immunotherapy is being increasingly investigated as a treatment for glioblastoma (GBM). Recent non-randomized clinical trials and…”
Get full text

OS1.1 Role of RNU6-1 isolated from circulating exosomes as a differential biomarker for GBM versus non-neoplasic brain lesions and PCNSL by Puigdelloses, M, González-Huarriz, M, Zandio, B, Besora, S, Bruna, J, Petrirena, G, Marigil, M, Díez-Valle, R, Tejada, S, Nuñez, J, Alonso, M, Gállego Pérez-Larraya, J

“…Abstract Background Glioblastoma (GBM) is the most common malignant primary brain tumour in adults, and is still associated with a dismal prognosis despite…”
Get full text

On the future of the young neurologist in Spain by Gállego Pérez-Larraya, J, Murie-Fernández, M, Irimia, P

Get more information

O6.03A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION AND RADIO-CHEMOTHERAPY FOLLOWING FLUORESCENCE-GUIDED SURGERY IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS: PRELIMINARY CLINICAL RESULTS OF THE «DEND/GBM» TRIAL by Gállego Pérez-Larraya, J., Tejada-Solís, S., de Cerio, A.L., Inogés, S., Espinós, J., Díez-Valle, R.

“…BACKGROUND: Immunotherapy is emerging as a promising therapeutic modality for the treatment of glioblastoma (GBM). Recent clinical trials have supported the…”
Get full text

Actualización en el diagnóstico de la encefalitis by Arbizu, J., Gállego Pérez-Larraya, J., Hilario, A., Gómez Grande, A., Rubí, S., Camacho, V.

Get full text

PO-1050 11C-Methionine-PET scan for target delineation in patients treated with IMPT for CNS tumors by Martin Pastor, S., Calvo Manuel, F.A., Garcia-Consuegra, A., Serrano Andreu, J., Arbizu Lostao, J., Gállego Pérez De Larraya, J., González Quarante, L.H., Dominguez Echávarri, P., Echeveste, J.I., Cambeiro, M., ázquez, V., Maria, R.R., Aristu Mendioroz, J., Suarez Vega, V.M.

Get full text

Clinical and neuroimaging characteristics of 14 patients with prionopathy: a descriptive study by Ortega-Cubero, S, Pagola, I, Luquin, M R, Viteri, C, Pastor, P, Gállego Pérez-Larraya, J, de Castro, P, Domínguez, I, Irimia, P, Martínez-Vila, E, Arbizu, J, Riverol, M

“…Prionopathy is the cause of 62% of the rapidly progressive dementias (RPD) in which a definitive diagnosis is reached. The variability of symptoms and signs…”
Get more information

O6.03 A PHASE II TRIAL OF AUTOLOGOUS DENDRITIC CELLS VACCINATION AND RADIO-CHEMOTHERAPY FOLLOWING FLUORESCENCE-GUIDED SURGERY IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS: PRELIMINARY CLINICAL RESULTS OF THE <<DEND/GBM>> TRIAL by Gallego Perez-Larraya, J., Tejada-Solis, S., de Cerio, A. L., Inoges, S., Espinos, J., Diez-Valle, R.

“…BACKGROUND: Immunotherapy is emerging as a promising therapeutic modality for the treatment of glioblastoma (GBM). Recent clinical trials have supported the…”
Get full text

Clasificación de los trastornos del sueño by Gállego Pérez-Larraya, J, Toledo, J. B, Urrestarazu, E, Iriarte, Jorge

“…Los trastornos del sueño son una patología muy frecuente tanto aislada, propia como tal, o asociada a otros trastornos. Sin embargo, es una parte de la…”
Get full text